Related Experiment Videos
Neuroblastoma: an enigmatic disease
J Brossard1, M L Bernstein, B Lemieux
1Department of Pediatrics, Centre universitaire de santé de l'Estrie, University of Sherbrooke, Quebec, Canada.
British Medical Bulletin
|October 1, 1996
Summary
Neuroblastoma, a common childhood cancer, is better understood through recent genetic and biologic discoveries. Infant screening shows promise in reducing mortality and advanced disease stages.
Area of Science:
- Pediatric Oncology
- Cancer Genetics
- Tumor Biology
Background:
- Neuroblastoma is the most frequent pediatric extra-cranial solid tumor, arising from neural crest cells.
- Recent advancements in genetics and biology have improved understanding of neuroblastoma's natural history and prognosis.
- Biochemical markers and age at diagnosis significantly influence survival outcomes.
Purpose of the Study:
- To review clinical aspects of neuroblastoma.
- To emphasize the genetic and biologic features influencing prognosis and treatment.
- To discuss infant screening experiences for neuroblastoma.
Main Methods:
- Review of clinical, genetic, and biologic features of neuroblastoma.
- Analysis of prognostic indicators.
- Discussion of infant screening programs, including the Quebec Neuroblastoma Screening Project.
Main Results:
- Improved understanding of neuroblastoma genetics and biology aids in prognosis and treatment.
- Infant screening aims to decrease mortality and advanced stage disease.
- Specific biochemical markers and age at diagnosis are critical prognostic factors.
Conclusions:
- Genetic and biologic insights are crucial for neuroblastoma management.
- Infant screening strategies warrant further investigation to improve outcomes.
- Understanding neuroblastoma's natural history informs therapeutic and screening approaches.